黑马Metsera:为辉瑞青睐的肽技术平台有何玄机?

研发客
Oct 04

//·Metsera崛起路径清晰,自2022年成立起,依托风险投资与基金支持,聚焦肽工程与给药技术创新,迅速完成多轮融资、纳斯达克IPO,于2025年9月被辉瑞高溢价收购。·公司并非简单、单一追随GLP-1热点,而是通过超长效注射、口服多肽及多靶点组合疗法三条路径,延长半衰期与口服给药,提高疗效和患者依从性、降低成本和API需求,同时拓展代谢病、罕见病、CNS及免疫疗法,显示肽类药物的多场景渗透力...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10